After yesterday's market close, the specialty orthopaedic company reported an adjusted loss of 8 cents per share, which was narrower than the loss of 33 cents per share analysts' were expecting.
Revenue for the period was $177 million, topping Wall Street's projects of $166.1 million.
In October, the company merged with Tornier, which designs, manufactures and markets devices for joint replacement and soft tissue repair.
"Following our merger, we have leading positions in the highest growth markets in orthopaedics with differentiated technologies and focused sales forces," CEO Robert Palmisano said in a statement.
"We have multiple opportunities through a robust new product pipeline to further accelerate our growth, continue to expand our markets and gain market share," he added.
For the full year, the company expects a loss of 65 cents per share to 71 cents per share on revenue between $695 million to $705 million.
Analysts are projecting a loss of 84 cents per share on revenue of $702 million for 2016.
Through subsidiaries, the company provides extremity and biologic solutions to alleviate pain.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.
This is driven by a few notable weaknesses, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally high debt management risk and generally disappointing historical performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: WMGI